Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of tenofovir‐based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy

Trial Profile

Study of tenofovir‐based salvage therapy for patients with chronic hepatitis B who previously failed LAM/ADV therapy

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 02 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary) ; Lamivudine
  • Indications Hepatitis B
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms TDF-109
  • Most Recent Events

    • 02 May 2018 New trial record
    • 01 Jun 2017 A total of 59 patients completed the first phase of the study and 54/59 were enrolled over into a long-term prospective open-label study of TDF with or without LAM 300 mg daily, as per the results published in the Liver International.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top